To evaluate the efficacy of different routes of administration of glucocorticoid nebulization and systemic therapy in diabetes mellitus type 2 (T2DM) patients combined with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
Patients with T2DM combined with AECOPD with good glycemic control in our respiratory department from July 2019 to December 2021 were included. All patients were randomly divided into control group, intravenous injection group and nebulized group by random number table method, 35 cases in each group. All patients received routine treatment. The control group was not routinely treated with glucocorticoids, the intravenous injection group received systemic glucocorticoid therapy with methylprednisolone sodium succinate, and the nebulized group inhaled budesonide. Pulmonary function, arterial blood gas indexes and blood glucose metabolism indexes were compared among the three groups after 1 week and 1 month after treatment.
Compared with the control group, forced expiratory volume in the first second [(1.32±0.13) L vs (1.21±0.17) L, (1.38±0.18) L vs (1.21±0.17) L, (1.41±0.14) L vs (1.31±0.15) L, (1.47±0.20) L vs (1.31±0.15) L] and arterial partial pressure of oxygen in intravenous injection group and nebulized group were significantly higher at 1 week and 1 month after treatment (P<0.05). In addition, the fasting blood glucose levels in intravenous injection group and nebulized group were significantly higher at 1 week and 1 month after treatment, but the nebulized group had less effect on fasting blood glucose than intravenous injection group [(8.10±0.34)mmol/L vs (6.38±0.58)mmol/L, (6.89±0.41)mmol/L vs (6.20±0.60)mmol/L](P<0.05).
In T2DM patients combined with AECOPD, glucocorticoids can significantly shortened the course of the disease, and the clinical effect was significantly better than that of conventional treatment. The clinical effect of aerosol inhalation was similar to that of systemic use of glucocorticoids, and aerosol inhalation was superior to systemic use in blood glucose control.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |